Oruka Therapeutics, Inc. (ABIO)
NASDAQ (CM) NASDAQ (CM) Primary Summary
ABIO Chart
Oruka Therapeutics, Inc. (ABIO) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Oruka Therapeutics, Inc. Profile
| - Industry | - Sector | Dr. Michael R. Bristow M.D., Ph.D. CEO | NASDAQ (CM) Exchange | 00211Y506 CUSIP |
| United States Country | 3 Employees | 28 Aug 2024 Last Dividend | 4 Sep 2015 Last Split | 8 Aug 1997 IPO Date |
Overview
ARCA biopharma, Inc. is recognized as a pioneering clinical stage biopharmaceutical company dedicated to the development and potential commercialization of targeted therapies for cardiovascular diseases. Operating from its headquarters in Westminster, Colorado, ARCA biopharma leverages its expertise in pharmacogenetics to create innovative treatments that address unmet medical needs in the cardiac care space. With a strategic focus on leveraging genetic insights to enhance the efficacy and safety of its product candidates, the company steps forward as a leader in cardiovascular genomics. Its collaboration with LabCorp for the development of a genetic test for its GENETIC-AF clinical trial underscores its commitment to cutting-edge research and personalized medicine.
Products and Services
- Gencaro
Gencaro represents ARCA biopharma's flagship candidate, positioned as a cutting-edge, pharmacogenetically-targeted beta-adrenergic receptor antagonist. Designed for patients suffering from atrial fibrillation coupled with heart failure, Gencaro has successfully navigated through a Phase IIb trial. Its development underscores the company's dedication to leveraging genetic insights for creating more effective, targeted therapies. Gencaro's distinct genetic targeting approach offers the potential for improved patient outcomes in the challenging field of cardiovascular diseases.
- Recombinant Nematode Anticoagulant Protein c2 (rNAPc2)
This novel protein therapeutic is currently under development for a rather unexpected application: the treatment of COVID-19. Having proceeded to a Phase IIb clinical trial, rNAPc2 exemplifies ARCA biopharma’s versatility and its innovative approach to drug development. Initially conceived for addressing cardiovascular issues due to its anticoagulant properties, rNAPc2's potential effectiveness in treating COVID-19-associated coagulation anomalies represents a significant pivot in its application, showcasing the company's ability to respond to emergent global health crises with agility and scientific acumen.
